<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1176" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1176/" /><meta name="ncbi_pagename" content="Nijmegen Breakage Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Nijmegen Breakage Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Nijmegen Breakage Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/02/02" /><meta name="citation_author" content="Raymonda Varon" /><meta name="citation_author" content="Ilja Demuth" /><meta name="citation_author" content="Krystyna H Chrzanowska" /><meta name="citation_pmid" content="20301355" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1176/" /><meta name="citation_keywords" content="Ataxia-Telangiectasia Variant 1" /><meta name="citation_keywords" content="Berlin Breakage Syndrome" /><meta name="citation_keywords" content="Nibrin" /><meta name="citation_keywords" content="NBN" /><meta name="citation_keywords" content="Nijmegen Breakage Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Nijmegen Breakage Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Raymonda Varon" /><meta name="DC.Contributor" content="Ilja Demuth" /><meta name="DC.Contributor" content="Krystyna H Chrzanowska" /><meta name="DC.Date" content="2017/02/02" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1176/" /><meta name="description" content="Nijmegen breakage syndrome (NBS) is characterized by progressive microcephaly, intrauterine growth retardation and short stature, recurrent sinopulmonary infections, an increased risk for cancer, and premature ovarian failure in females. Developmental milestones are attained at the usual time during the first year; however, borderline delays in development and hyperactivity may be observed in early childhood. Intellectual abilities tend to decline over time and most children tested after age seven years have mild to moderate intellectual disability. Recurrent pneumonia and bronchitis may result in respiratory failure and early death. Approximately 40% of affected individuals have developed malignancies before age 20 years, with the risk being highest for T-cell (55%) and B-cell lymphomas (45%). Other tumors include solid tumors (e.g., medulloblastoma, glioma, and rhabdomyosarcoma). Note, however, that much of what is reported about NBS is based on individuals who are homozygous for the single most common Eastern European pathogenic variant, c.657_661del5." /><meta name="og:title" content="Nijmegen Breakage Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Nijmegen breakage syndrome (NBS) is characterized by progressive microcephaly, intrauterine growth retardation and short stature, recurrent sinopulmonary infections, an increased risk for cancer, and premature ovarian failure in females. Developmental milestones are attained at the usual time during the first year; however, borderline delays in development and hyperactivity may be observed in early childhood. Intellectual abilities tend to decline over time and most children tested after age seven years have mild to moderate intellectual disability. Recurrent pneumonia and bronchitis may result in respiratory failure and early death. Approximately 40% of affected individuals have developed malignancies before age 20 years, with the risk being highest for T-cell (55%) and B-cell lymphomas (45%). Other tumors include solid tumors (e.g., medulloblastoma, glioma, and rhabdomyosarcoma). Note, however, that much of what is reported about NBS is based on individuals who are homozygous for the single most common Eastern European pathogenic variant, c.657_661del5." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1176/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/nijmegen/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1176/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88EFBEE040D1D10000000000260011.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1176_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1176_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/npc/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/nkh/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1176_"><span class="title" itemprop="name">Nijmegen Breakage Syndrome</span></h1><p class="contrib-group"><span itemprop="author">Raymonda Varon</span>, PhD, <span itemprop="author">Ilja Demuth</span>, PhD, and <span itemprop="author">Krystyna H Chrzanowska</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1176_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1176_ai__"><div class="contrib half_rhythm"><span itemprop="author">Raymonda Varon</span>, PhD<div class="affiliation small">Institute of Medical and Human Genetics<br />Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin<br />Berlin, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.etirahc@aveetam-norav.adnomyar" class="oemail">ed.etirahc@aveetam-norav.adnomyar</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Ilja Demuth</span>, PhD<div class="affiliation small">Institute of Medical and Human Genetics<br />Charit&#x000e9; &#x02013; Universit&#x000e4;tsmedizin Berlin<br />Berlin, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.etirahc@htumed.ajlI" class="oemail">ed.etirahc@htumed.ajlI</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Krystyna H Chrzanowska</span>, MD, PhD<div class="affiliation small">The Children&#x02019;s Memorial Health Institute<br />Warsaw, Poland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="lp.dzcpi@akswonazrhc.k" class="oemail">lp.dzcpi@akswonazrhc.k</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">May 17, 1999</span>; Last Update: <span itemprop="dateModified">February 2, 2017</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="nijmegen.Summary" itemprop="description"><h2 id="_nijmegen_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Nijmegen breakage syndrome (NBS) is characterized by progressive microcephaly, intrauterine growth retardation and short stature, recurrent sinopulmonary infections, an increased risk for cancer, and premature ovarian failure in females. Developmental milestones are attained at the usual time during the first year; however, borderline delays in development and hyperactivity may be observed in early childhood. Intellectual abilities tend to decline over time and most children tested after age seven years have mild to moderate intellectual disability. Recurrent pneumonia and bronchitis may result in respiratory failure and early death. Approximately 40% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have developed malignancies before age 20 years, with the risk being highest for T-cell (55%) and B-cell lymphomas (45%). Other tumors include solid tumors (e.g., medulloblastoma, glioma, and rhabdomyosarcoma). Note, however, that much of what is reported about NBS is based on individuals who are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the single most common Eastern European <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, c.657_661del5.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of NBS is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the clinical findings listed above who has <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>NBN</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> and/or absent nibrin protein on immunoblotting assay.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Vitamin E and folic acid supplementation; use of IVIg in individuals with severe humoral immunodeficiency and frequent infections; standard chemotherapy protocols for lymphoid malignancies (adopted to individual tolerance); consideration of hematopoietic stem cell transplantation; hormone replacement therapy for females who have hypergonadotropic hypogonadism.</p><p><i>Surveillance:</i></p><ul><li class="half_rhythm"><div>For <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals: Periodic follow up to monitor developmental progress, physical growth and infection frequency; in those with weight loss, assessment for malignancy should be considered; lifelong monitoring of immune biomarkers; careful monitoring by an oncologist; monitoring for pubertal progression in both sexes and premature ovarian insufficiency in females; breast self-examination and ultrasonographic evaluation.</div></li><li class="half_rhythm"><div>For carriers (heterozygotes): Parents should be monitored for malignancy, particularly breast cancer in women and prostate cancer in men.</div></li></ul><p><i>Agents/circumstances to avoid:</i> Because the cells from individuals with NBS are radiosensitive in vitro, doses of radiation used in radiotherapy need to be reduced. Unnecessary exposure to imaging studies that use ionizing radiation (plain radiograph, CT scan) should be avoided and use of MRI and/or ultrasound considered.</p><p><i>Evaluation of relatives at risk</i>: Molecular genetic testing for the <i>NBN</i> pathogenic variants identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> should be offered to apparently asymptomatic sibs of a proband and young adult relatives at risk of being carriers (heterozygotes) in order to identify as early as possible those who would benefit from monitoring for malignancy and to inform treatment options if a malignancy is diagnosed.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>NBS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal testing are possible if both of the pathogenic variants have been identified in an affected family member.</p></div></div><div id="nijmegen.Diagnosis"><h2 id="_nijmegen_Diagnosis_">Diagnosis</h2><div id="nijmegen.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Nijmegen breakage syndrome (NBS) <b>should be suspected</b> in individuals with the following clinical and supportive laboratory findings.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div><b>Disproportionate microcephaly</b> that is progressive</div></li><li class="half_rhythm"><div><b>Craniofacial features</b> that include a sloping forehead, upward slanted palpebral fissures, prominent nose, relatively large ears, and retrognathia</div></li><li class="half_rhythm"><div><b>Growth retardation</b> that is more pronounced from birth until the age of three years, with mild improvement thereafter</div></li><li class="half_rhythm"><div><b>Recurrent infections</b> including pneumonia, bronchitis, sinusitis, otitis media, and mastoiditis</div></li><li class="half_rhythm"><div><b>Malignancies,</b> predominantly of lymphoid origin</div></li><li class="half_rhythm"><div><b>Decline in intellectual ability,</b> from normal or borderline-normal during early childhood to moderate intellectual disability in older individuals</div></li></ul><p><b>Supportive laboratory findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Immunodeficiency</b> involving the humoral and cellular systems [<a class="bk_pop" href="#nijmegen.REF.gregorek.2002.319">Gregorek et al 2002</a>, <a class="bk_pop" href="#nijmegen.REF.micha_kiewicz.2003.482">Micha&#x00142;kiewicz et al 2003</a>, <a class="bk_pop" href="#nijmegen.REF.wolskaku_nierz.2015.538">Wolska-Ku&#x0015b;nierz et al 2015</a>]:</div><ul><li class="half_rhythm"><div>Severe hypogammaglobulinemia has been found in 20%-24% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and IgA deficiency in 50%-57%.</div></li><li class="half_rhythm"><div>Deficiencies of IgG2 and IgG4 are frequent even when the IgG serum concentration is normal.</div></li><li class="half_rhythm"><div>The most commonly reported defects in cellular immunity include reduced absolute numbers of total B cells, CD3+ T cells, and CD4+ cells; observed in 80%-89% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li><li class="half_rhythm"><div>An increased frequency of T cells with a memory <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (CD45RO+) and a concomitant decrease in na&#x000ef;ve T cells (CD45RA+) has been reported.</div></li><li class="half_rhythm"><div>The in vitro proliferation of T and B lymphocytes to antigen and/or mitogenic stimuli is greatly reduced in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Chromosome instability</b></div><ul><li class="half_rhythm"><div>Inversions and translocations involving chromosomes 7 and 14 are observed in PHA-stimulated lymphocytes in 10%-50% of metaphases.</div></li><li class="half_rhythm"><div>The breakpoints most commonly involved are 7p13, 7q35, 14q11, and 14q32, which are the loci for immunoglobulin and T cell-receptor genes.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Radiation <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a>.</b> Cells from individuals with NBS have a decrease in colony-forming ability following exposure to ionizing radiation and radiomimetics in vitro.</div><div class="half_rhythm">Note: This test requires that a lymphoblastoid cell line be established. Because this process is more commonly performed in a research lab than in a clinical lab, the test may not be widely available clinically.</div></li></ul></div><div id="nijmegen.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of NBS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the <a href="#nijmegen.Suggestive_Findings">clinical features</a> above who has <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>NBN</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.molecular_genetic_testing_use/?report=objectonly" target="object" rid-figpopup="fignijmegenTmoleculargenetictestinguse" rid-ob="figobnijmegenTmoleculargenetictestinguse">Table 1</a>) and/or absent nibrin protein on an immunoblotting assay (see <b>Immunoblotting</b>; below <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.molecular_genetic_testing_use/?report=objectonly" target="object" rid-figpopup="fignijmegenTmoleculargenetictestinguse" rid-ob="figobnijmegenTmoleculargenetictestinguse">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div>Targeted analysis for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.657_661del5 can be performed first. The c.657_661del5 pathogenic variant is detected in:</div><ul><li class="half_rhythm"><div>~100% of alleles in individuals of Slavic (Poland, Czech Republic, Ukraine) ancestry;</div></li><li class="half_rhythm"><div>~70% of alleles in individuals of North American ancestry.</div></li></ul></li><li class="half_rhythm"><div>If the common <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is not present in a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> form, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of <i>NBN</i> can be pursued.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>NBN</i> and other genes of interest (see <a href="#nijmegen.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="nijmegen.T.molecular_genetic_testing_use" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Nijmegen Breakage Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1176/table/nijmegen.T.molecular_genetic_testing_use/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nijmegen.T.molecular_genetic_testing_use_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>NBN</i></td><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for c.657_661del5 variant&#x000a0;<sup>3</sup></td><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%-100%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup></td><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~100%</td></tr><tr><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>8</sup></td><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_nijmegen.T.molecular_genetic_testing_use_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="nijmegen.TF.1.1"><p class="no_margin">See <a href="/books/NBK1176/#nijmegen.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="nijmegen.TF.1.2"><p class="no_margin">See <a href="#nijmegen.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="nijmegen.TF.1.3"><p class="no_margin">Methods that may be used to detect the <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">c.657_661del5</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can include: <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>-specific <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a>, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, and <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a> assays designed to this variant. Note that these assays may not detect variants other than the targeted variant.</p></div></dd><dt>4. </dt><dd><div id="nijmegen.TF.1.4"><p class="no_margin">Nearly all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals from Poland, the Czech Republic, and Ukraine tested to date are <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">c.657_661del5</a>. In a study of eight unrelated individuals with NBS from the Russian population, <a class="bk_pop" href="#nijmegen.REF.resnick.2002.355">Resnick et al [2002]</a> found that all but one of the 16 alleles were c.657_661del5. In the US, about 70% of individuals tested to date are homozygous for the common <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>, 15% are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for c.657_661del5 and a second unique pathogenic variant, and 15% are homozygous for a unique pathogenic variant. In the US patient population, almost all affected individuals who have the <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">c.657_661del5</a> pathogenic variant are of known Eastern European ancestry.</p></div></dd><dt>5. </dt><dd><div id="nijmegen.TF.1.5"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>6. </dt><dd><div id="nijmegen.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="nijmegen.TF.1.7"><p class="no_margin">No deletions or duplications involving this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> have been reported to cause NBS.</p></div></dd><dt>8. </dt><dd><div id="nijmegen.TF.1.8"><p class="no_margin"><i>NBN</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> associated with NBS; however, because NBS is clinically similar to other disorders (see <a href="#nijmegen.Differential_Diagnosis">Differential Diagnosis</a>), many individuals referred for diagnostic testing for NBS based on clinical findings and radiosensitivity lack identified pathogenic variants in <i>NBN</i> [Author, unpublished observation]. Presently, distinction can only be made by excluding pathogenic variants in <i>NBN</i>.</p></div></dd></dl></div></div></div><p><b>Immunoblotting</b> can be used to determine if the nibrin protein is present or absent.</p><p>Note: This test requires that a lymphoblastoid cell line be established. Because this process is more commonly performed in a research lab than in a clinical lab, the test may not be widely available clinically.</p></div></div><div id="nijmegen.Clinical_Characteristics"><h2 id="_nijmegen_Clinical_Characteristics_">Clinical Characteristics</h2><div id="nijmegen.Clinical_Description"><h3>Clinical Description</h3><p><b>Growth.</b> Children with Nijmegen breakage syndrome (NBS) generally are born with weight below normal for gestational age and microcephaly (i.e., head circumference &#x0003e;2 SD below the mean for age and gender). Microcephaly progresses with age &#x02013; in contrast to linear growth, which may improve with age, causing disproportionate head dimensions compared to the rest of the body. Microcephaly is occasionally masked by hydrocephaly or developmental abnormalities of the brain [Szcza&#x00142;uba 2012].</p><p>Growth failure in the early stages of life results in length/height that is usually below the third centile by age two years. Thereafter, linear growth velocity tends to normalize, however many individuals remain shorter than peers (i.e., <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals do not experience catch-up growth). Some adults, both females and males, can achieve height within lower normal ranges [<a class="bk_pop" href="#nijmegen.REF.chrzanowska.2012.13">Chrzanowska et al 2012</a>].</p><p><b>Craniofacial features.</b> The craniofacial features discussed in <a href="#nijmegen.Suggestive_Findings">Suggestive Findings</a> are found in the majority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and become more pronounced with age as microcephaly progresses.</p><p><b>Infections.</b> Respiratory infections are the most common. Recurrent pneumonia and bronchitis may result in bronchiectasis, and even in pulmonary failure and early death. Chronic diarrhea and urinary tract infections may also occur.</p><p><b>Malignancy.</b> According to <a class="bk_pop" href="#nijmegen.REF.chrzanowska.2012.13">Chrzanowska et al [2012]</a>, 40% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals reported to date have developed malignancies before age 20 years. Malignancies are primarily lymphomas [<a class="bk_pop" href="#nijmegen.REF.g_adkowskadura.2008.337">G&#x00142;adkowska-Dura et al 2008</a>, <a class="bk_pop" href="#nijmegen.REF.wolskaku_nierz.2015.538">Wolska-Ku&#x0015b;nierz et al 2015</a>]. Approximately 45% of lymphomas are of B cell origin and 55% are T cell lymphomas. Several children have developed solid tumors, including medulloblastomas, glioma, and rhabdomyosarcoma [<a class="bk_pop" href="#nijmegen.REF.hiel.2001.e19">Hiel et al 2001</a>, <a class="bk_pop" href="#nijmegen.REF.bakhshi.2003.248">Bakhshi et al 2003</a>, <a class="bk_pop" href="#nijmegen.REF.distel.2003.44">Distel et al 2003</a>, <a class="bk_pop" href="#nijmegen.REF.meyer.2004.169">Meyer et al 2004</a>].</p><p><b>Psychomotor and intellectual development.</b> Developmental milestones are attained at the usual time during the first year. Normal or borderline intellectual development and psychomotor hyperactivity may be observed in early childhood/pre-school age. Intellectual abilities tend to decline from mild to moderate intellectual disability during childhood. Affected children are described as having a cheerful, shy personality with good interpersonal skills.</p><p><b>Fertility.</b> Two reports of gonadal dysfunction in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females with <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> instability disorder / syndrome appeared in 1986 [<a class="bk_pop" href="#nijmegen.REF.maraschio.1986.353">Maraschio et al 1986</a>]. Twenty years later, <a class="bk_pop" href="#nijmegen.REF.varon.2006.679">Varon et al [2006]</a> identified <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">c.741_742dup</a> variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 of <i>NBN</i> one of the original women reported by <a class="bk_pop" href="#nijmegen.REF.maraschio.1986.353">Maraschio and colleagues [1986]</a>.</p><p><a class="bk_pop" href="#nijmegen.REF.chrzanowska.2000.s73">Chrzanowska et al [2000]</a> originally presented observations that strongly suggested an increased risk of premature ovarian failure in women with NBS. Results of a longitudinal study demonstrated that hypergonadotropic hypogonadism was present in a large cohort of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females, all of whom were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the common <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">c.657_661del5</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#nijmegen.REF.chrzanowska.2010a.3133">Chrzanowska et al 2010a</a>].</p><p>No detailed studies of fertility in males with NBS have been published; however, puberty initiation and progress are comparable to healthy boys [<a class="bk_pop" href="#nijmegen.REF.chrzanowska.2010b.88">Chrzanowska et al 2010b</a>]. <a class="bk_pop" href="#nijmegen.REF.warcoin.2009.424">Warcoin et al [2009]</a> described two adult siblings, a male with oligo-terato-asthenozoospermia and a female with premature ovarian failure, who had <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> truncating variants in <i>NBN</i> but none of the other clinical features of NBS.</p><p><b>Other findings</b></p><ul><li class="half_rhythm"><div>Irregular skin pigmentation in the form of irregular hyperpigmented or hypopigmented macules is seen in most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. In some affected individuals, progressive sarcoid-like granulomas are observed [<a class="bk_pop" href="#nijmegen.REF.yoo.2008.418">Yoo et al 2008</a>, <a class="bk_pop" href="#nijmegen.REF.pasic.2012.138">Pasic et al 2012</a>].</div></li><li class="half_rhythm"><div>Congenital malformations, usually observed in single cases, include anomalies of the central nervous system (e.g., hydrocephaly, schizencephaly, arachnoid cysts), choanal atresia, cleft lip and palate, tracheal hypoplasia, preaxial or postaxial polydactyly, horseshoe kidney, hydronephrosis, hypospadias, anal stenosis/atresia, and <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> hip dysplasia.</div></li></ul><p><b>Heterozygotes.</b> Heterozygotes are asymptomatic, however, there is clear evidence of increased cancer occurrence among <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> relatives of individuals with NBS in the Czech Republic [<a class="bk_pop" href="#nijmegen.REF.seemanov_.2007.1875">Seemanov&#x000e1; et al 2007</a>]. Furthermore, an increased frequency of the pathogenic <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">c.657_661del5</a> variant in <i>NBN</i> has been observed in several different cancers including breast cancer, prostate cancer, medulloblastoma, and melanoma, suggesting that pathogenic variants in <i>NBN</i> might play a role in the etiology of these types of cancer [<a class="bk_pop" href="#nijmegen.REF.cybulski.2004.1215">Cybulski et al 2004</a>, <a class="bk_pop" href="#nijmegen.REF.steffen.2004.67">Steffen et al 2004</a>, <a class="bk_pop" href="#nijmegen.REF.ciara.2010.325">Ciara et al 2010</a>].</p></div><div id="nijmegen.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, c.657_661del5, and most other <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants result in a classic presentation. However, exceptions have been reported. There are two reports of families in which <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> truncating variants in <i>NBN</i> occur in individuals with milder features:</p><ul><li class="half_rhythm"><div><a class="bk_pop" href="#nijmegen.REF.varon.2006.679">Varon et al [2006]</a> described a 53-year-old woman who was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>NBN</i> truncating <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">c.741_742dupGG</a>. This <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> woman had a somewhat milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> including microcephaly, <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> instability, immunodeficiency, and primary amenorrhea. Her sister, with similar clinical manifestations died at 20 years of malignant lymphoma [<a class="bk_pop" href="#nijmegen.REF.maraschio.1986.353">Maraschio et al 1986</a>]. However, analysis of transcripts from the affected individual&#x02019;s cells indicated a highly prevalent alternatively spliced form of <i>NBN</i> lacking exons 6 and 7 (where the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is located). This transcript produces a 73-kd form of NBN with an internal <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>.</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#nijmegen.REF.warcoin.2009.424">Warcoin et al [2009]</a> described a family in which two healthy adult sibs, a sister and a brother, had <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> truncating variants in <i>NBN</i> (p.Tyr110Ter and <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">p.Trp375Ter</a>). Both were normal on clinical examination and did not have any evidence of short stature, reduced head circumference, or facial <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features; however, both were referred for fertility defects and were subsequently found to have the cellular phenotypes typical of NBS including <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> instability, hypersensitivity to ionizing radiation, and impaired checkpoint responses.</div></li></ul></div><div id="nijmegen.Nomenclature"><h3>Nomenclature</h3><p>The Nijmegen breakage syndrome was described by <a class="bk_pop" href="#nijmegen.REF.weemaes.1981.557">Weemaes et al [1981]</a>.</p><p>Three Czech families with Seemanov&#x000e1; syndrome [<a class="bk_pop" href="#nijmegen.REF.seemanov_.1985.639">Seemanov&#x000e1; et al 1985</a>] were later identified as having NBS.</p><p>Genetic complementation studies are no longer of clinical importance. The report of <a class="bk_pop" href="#nijmegen.REF.jaspers.1988.259">Jaspers et al [1988]</a> noted a strong similarity between NBS cells and <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a> (A-T) cells; however, they also described the NBS cells as genetically distinct from A-T, grouping individuals with either Nijmegen breakage syndrome or Czech breakage syndrome into A-T variant group V1 and Germans with "Berlin breakage syndrome" [<a class="bk_pop" href="#nijmegen.REF.wegner.1999">Wegner et al 1999</a>] into A-T variant group V2 [<a class="bk_pop" href="#nijmegen.REF.jaspers.1988.259">Jaspers et al 1988</a>]. Subsequently, <i>NBN</i> pathogenic variants were found in all individuals studied from the A-T variant groups V1 and V2, indicating that these individuals had NBS, not ataxia-telangiectasia.</p></div><div id="nijmegen.Prevalence"><h3>Prevalence</h3><p>No reliable estimates of world-wide prevalence exist, but it is likely to approximate 1:100,000 live births.</p><p>NBS is most common in Eastern European/Slavic populations. Studies in Poland, the Czech Republic, and the Ukraine have suggested that the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of the common <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> approaches 1:155 in these populations. The highest reported prevalence is in Sorbians, a Slavic population isolate from southeastern Germany, in whom the carrier frequency is estimated at 1:34 [<a class="bk_pop" href="#nijmegen.REF.maurer.2010.211">Maurer et al 2010</a>].</p></div></div><div id="nijmegen.Genetically_Related_Disorders"><h2 id="_nijmegen_Genetically_Related_Disorders_">Genetically Related Disorders</h2><p>Individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <i>NBN</i>
<a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">c.1089C&#x0003e;A</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have features of <a href="/books/n/gene/fa/">Fanconi anemia</a> [<a class="bk_pop" href="#nijmegen.REF.gennery.2004.214">Gennery et al 2004</a>].</p></div><div id="nijmegen.Differential_Diagnosis"><h2 id="_nijmegen_Differential_Diagnosis_">Differential Diagnosis</h2><p>Microcephaly, growth delay, immunodeficiency, and/or bone marrow failure are common manifestations of several inherited disorders, mainly related to defective sensing, processing, and repair of double-strand DNA breaks. Recurrent infections, poor growth, and immunodeficiency can be observed in other inherited immunodeficiencies. See <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.disorders_to_consider_in_the/?report=objectonly" target="object" rid-figpopup="fignijmegenTdisorderstoconsiderinthe" rid-ob="figobnijmegenTdisorderstoconsiderinthe">Table 2</a>.</p><p>The early growth failure in Nijmegen breakage syndrome (NBS) may suggest other disorders of growth, such as thyroid hormone or growth hormone deficiency, or primary disorders of bone growth (i.e., skeletal dysplasias).</p><p>Because malignancy may be the presenting finding in NBS, the diagnosis of NBS should be considered before radiotherapy is initiated in individuals with microcephaly who have solid tumors and are younger than age three years [<a class="bk_pop" href="#nijmegen.REF.bakhshi.2003.248">Bakhshi et al 2003</a>, <a class="bk_pop" href="#nijmegen.REF.distel.2003.44">Distel et al 2003</a>, <a class="bk_pop" href="#nijmegen.REF.meyer.2004.169">Meyer et al 2004</a>].</p><div id="nijmegen.T.disorders_to_consider_in_the" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Nijmegen Breakage Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1176/table/nijmegen.T.disorders_to_consider_in_the/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nijmegen.T.disorders_to_consider_in_the_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disease Name</th><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Immunodeficiency and/or<br />Bone Marrow Failure</th><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly /<br />Craniofacial Features</th><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Growth Delay</th><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cellular Sensitivity</th><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chromosome Instability</th><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cancer Predisposition</th><th id="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other</th></tr></thead><tbody><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nijmegen breakage syndrome</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NBN</i></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Immunodeficiency, combined; recurrent sinopulmonary infections</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive disproportionate microcephaly&#x000a0;<sup>1</sup>; characteristic facial features&#x000a0;<sup>2</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild growth restriction</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Decrease in colony-forming ability after exposure to ionizing radiation &#x00026; radiomimetics</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inversions &#x00026; translocations involving chromosomes 7 &#x00026; 14 in lymphocytes</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Increased risk, mainly of lymphoid origin</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Primary ovarian failure; mild-to-moderate intellectual disability</td></tr><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LIG4</i> syndrome&#x000a0;<sup>3</sup><br />OMIM <a href="http://omim.org/entry/606593" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606593</a></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LIG4</i></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Immunodeficiency combined; pancytopenia &#x00026; myelodysplastic syndrome</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly; facial features resembling NBS&#x000a0;<sup>2</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe radiosensitivity</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Increased <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage rate</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predisposition to malignancy (mainly lymphoma &#x00026; leukemia)</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High intrafamilial clinical variability</td></tr><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NHEJ1</i> syndrome<br />OMIM <a href="http://omim.org/entry/611291" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">611291</a></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NHEJ1</i></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild immunodeficiency to severe combined immunodeficiency</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe (typically) growth restriction</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cellular sensitivity to ionizing radiation</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">High <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> breakage rate (w/out <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 7;14 rearrangements)&#x000a0;<sup>4</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Limited data; unknown</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature, microcephaly, and endocrine dysfunction&#x000a0;<i><sup>5</sup></i><br />OMIM <a href="http://omim.org/entry/616541" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616541</a></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>XRCC4</i>&#x000a0;<sup>6</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No clinical manifestations of immunodeficiency</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Primary microcephaly</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe growth restriction</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pronounced cellular radiosensitivity</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not reported</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Solid tumor</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Primary ovarian failure; early-onset metabolic syndrome</td></tr><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Nijmegen breakage syndrome-like disorder<br />(RAD50 deficiency)&#x000a0;<sup>7,&#x000a0;8</sup><br />OMIM <a href="http://omim.org/entry/613078" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613078</a></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>RAD50</i></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No immunodeficiency</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly; facial features resembling NBS&#x000a0;<sup>2</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe growth restriction</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">X-ray hypersensitivity</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chromosome instability (incl. 7;14 rearrangements) in lymphocytes &#x00026; fibroblasts</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Limited data; unknown</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal puberty; disturbed sensorimotor coordination; intellectual disability</td></tr><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/fa/">Fanconi anemia<sup>&#x000a0;</sup></a><sup>9</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">18 genes&#x000a0;<sup>10</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive bone marrow failure (pancytopenia); myelodysplastic syndrome</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly (1/3 of individuals)</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Growth restriction</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cellular sensitivity to ionizing radiation &#x00026; DNA cross-linking agents&#x000a0;<sup>11</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chromosome breakage induced by mitomycin C &#x00026; diepoxybutane</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Myeloblastic leukemia; solid tumors</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Limited fertility</td></tr><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/ataxia-telangiectas/">Ataxia-telangiectasia</a></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATM</i> (A-T<sub>Fresno</sub>)&#x000a0;<sup>12</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No increased risk of infections</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Growth restriction</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypersensitivity to ionizing radiation</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chromosome instability (incl. 7;14 rearrangements) in lymphocytes</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Leukemia; Hodgkin &#x00026; non-Hodgkin lymphoma</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Scleral telangiectasia; progressive truncal ataxia; intellectual disability</td></tr><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seckel syndrome&#x000a0;<sup>13</sup><br />OMIM <a href="http://omim.org/phenotypicSeries/PS210600" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS210600</a></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 14</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Pancytopenia</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe microcephaly</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe growth restriction</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not typically radiosensitive by colony survival assay&#x000a0;<sup>13</sup></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Increased <a class="def" href="/books/n/gene/glossary/def-item/sister-chromatid-exchange/">sister chromatid exchange</a></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Limited data, possible myelodyplasia</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intellectual disability</td></tr><tr><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/rsts/">Rubinstein-Taybi syndrome</a></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>CREBBP</i><br /><i>EP300</i></td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Recurrent infections; defect in polysaccharide antibody response</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Microcephaly; distinctive facial features</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild growth restriction; short stature</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No cellular sensitivity</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not present</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Leukemia; tumors that affect the head</td><td headers="hd_h_nijmegen.T.disorders_to_consider_in_the_1_1_1_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intellectual disability</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="nijmegen.TF.2.1"><p class="no_margin"><a class="bk_pop" href="#nijmegen.REF.seeman.2004.195">Seeman et al [2004]</a> suggest that <i>NBN</i> pathogenic variants account for a significant number of children with primary microcephaly in the Czech Republic.</p></div></dd><dt>2. </dt><dd><div id="nijmegen.TF.2.2"><p class="no_margin">Facial features characteristic of Nijmegen breakage syndrome are: a sloping forehead, retrognathia, prominent nasal bridge and nose, large ears, and upslanted palpebral fissures.</p></div></dd><dt>3. </dt><dd><div id="nijmegen.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#nijmegen.REF.odriscoll.2001.1175">O'Driscoll et al [2001]</a>, <a class="bk_pop" href="#nijmegen.REF.benomran.2005.283">Ben-Omran et al [2005]</a>, <a class="bk_pop" href="#nijmegen.REF.altmann.2016.137">Altmann &#x00026; Gennery [2016]</a></p></div></dd><dt>4. </dt><dd><div id="nijmegen.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#nijmegen.REF.dutrannoy.2010.1059">Dutrannoy et al [2010]</a></p></div></dd><dt>5. </dt><dd><div id="nijmegen.TF.2.5"><p class="no_margin"><a class="bk_pop" href="#nijmegen.REF.murray.2015.412">Murray et al [2015]</a>, <a class="bk_pop" href="#nijmegen.REF.rosin.2015.3708">Rosin et al [2015]</a></p></div></dd><dt>6. </dt><dd><div id="nijmegen.TF.2.6"><p class="no_margin">XRCC4 is another component of the non-homologous end joining (NHEJ) pathway.</p></div></dd><dt>7. </dt><dd><div id="nijmegen.TF.2.7"><p class="no_margin">As only one individual with <i>RAD50</i> pathogenic variants has been described, it is unclear how consistent the clinical features of RAD50 deficiency appear to overlap with NBS.</p></div></dd><dt>8. </dt><dd><div id="nijmegen.TF.2.8"><p class="no_margin"><a class="bk_pop" href="#nijmegen.REF.barbi.1991.44">Barbi et al [1991]</a>, <a class="bk_pop" href="#nijmegen.REF.waltes.2009.605">Waltes et al [2009]</a></p></div></dd><dt>9. </dt><dd><div id="nijmegen.TF.2.9"><p class="no_margin">Overlap of some clinical features and cellular sensitivity to ionizing radiation and DNA cross-linking agents could lead to misdiagnosis of NBS as Fanconi anemia [<a class="bk_pop" href="#nijmegen.REF.gennery.2004.214">Gennery et al 2004</a>, <a class="bk_pop" href="#nijmegen.REF.new.2005.494">New et al 2005</a>].</p></div></dd><dt>10. </dt><dd><div id="nijmegen.TF.2.10"><p class="no_margin">Fanconi anemia is associated with mutation of <i>BRCA2, BRIP1, ERCC4</i>, <i>FANCA</i>, <i>FANCB</i>, <i>FANCC</i>, <i>FANCD2</i>, <i>FANCE</i>, <i>FANCF</i>, <i>FANCG</i>, <i>FANCI</i>, <i>FANCL</i>, <i>FANCM</i>, <i>PALB2</i>, <i>RAD51</i>, <i>RAD51C</i>, <i>SLX4</i>, or <i>UBE2T.</i></p></div></dd><dt>11. </dt><dd><div id="nijmegen.TF.2.11"><p class="no_margin">Increased sensitivity of lymphocytes to alkylating agents like mitomycin C and/or diepoxybutane is the cellular marker of Fanconi anemia and is used as a diagnostic aid.</p></div></dd><dt>12. </dt><dd><div id="nijmegen.TF.2.12"><p class="no_margin">Occasionally individuals with the <i>ATM</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> A-T<sub>Fresno</sub> have symptoms of both Nijmegen breakage syndrome and ataxia-telangiectasia (A-T) [<a class="bk_pop" href="#nijmegen.REF.curry.1989.270">Curry et al 1989</a>, <a class="bk_pop" href="#nijmegen.REF.gilad.1998.551">Gilad et al 1998</a>].</p></div></dd><dt>13. </dt><dd><div id="nijmegen.TF.2.13"><p class="no_margin"><a class="bk_pop" href="#nijmegen.REF.odriscoll.2003.497">O'Driscoll et al [2003]</a></p></div></dd><dt>14. </dt><dd><div id="nijmegen.TF.2.14"><p class="no_margin">OMIM <a href="http://omim.org/phenotypicSeries/PS210600" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS210600</a></p></div></dd></dl></div></div></div></div><div id="nijmegen.Management"><h2 id="_nijmegen_Management_">Management</h2><div id="nijmegen.Evaluations_Following_Initial_D"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Nijmegen breakage syndrome (NBS), the following evaluations are recommended (if they were not performed as part of the diagnostic evaluation):</p><ul><li class="half_rhythm"><div>Assessment of growth</div></li><li class="half_rhythm"><div>Evaluation of immunologic status to include:</div><ul><li class="half_rhythm"><div>Complete blood count;</div></li><li class="half_rhythm"><div>Absolute number of B-cells, T-cells, and T-cell subsets, with special attention to na&#x000ef;ve CD4+CD45RA cells;</div></li><li class="half_rhythm"><div>Proliferative response of peripheral blood mononuclear cells to stimuli;</div></li><li class="half_rhythm"><div>Concentration of total serum immunoglobulins (IgG, IgA, IgM) and IgG subclasses;</div></li><li class="half_rhythm"><div>Evaluation for viruses with lymphotrotropic capacity (i.e., EBV and CMV).</div></li></ul></li><li class="half_rhythm"><div>Evaluation for malignancy, including a focused family history of other individuals with cancer</div></li><li class="half_rhythm"><div>Evaluation of the endocrinologic status in females who are of pubertal age to include pelvic ultrasound to evaluate for streak gonads and plasma levels of FSH, LH, and estrogen [<a class="bk_pop" href="#nijmegen.REF.chrzanowska.2010a.3133">Chrzanowska et al 2010a</a>]</div></li><li class="half_rhythm"><div>Assessment of cognitive development and intellectual abilities</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="nijmegen.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Nutrition.</b> Because of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> instability, vitamin E and folic acid supplementation in doses appropriate for body weight is recommended.</p><p><b>Infections.</b> In individuals with severe humoral immunodeficiency and frequent infections, Ig replacement therapy should be considered.</p><ul><li class="half_rhythm"><div>Ig replacement is typically administered either intravenously (IVIg) or subcutaneously (SCIg).</div></li><li class="half_rhythm"><div>The spectrum of recurrent infections in NBS is not opportunistic; therefore, the antibiotic selected should be appropriate for the microorganism being treated.</div></li></ul><p><b>Malignancy.</b> Standard treatment chemotherapy protocols for lymphoid malignancies in NBS need to be adopted according to individual tolerance [<a class="bk_pop" href="#nijmegen.REF.dembowskabaginska.2009.186">Dembowska-Baginska et al 2009</a>, <a class="bk_pop" href="#nijmegen.REF.pastorczak.2016.126">Pastorczak et al 2016</a>]. Treatment of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with solid tumors is also challenging. Radiotherapy of CNS tumors (medulloblastoma) caused severe complications and death in three individuals with NBS [<a class="bk_pop" href="#nijmegen.REF.chrzanowska.1997.309">Chrzanowska et al 1997</a>, <a class="bk_pop" href="#nijmegen.REF.bakhshi.2003.248">Bakhshi et al 2003</a>, <a class="bk_pop" href="#nijmegen.REF.distel.2003.44">Distel et al 2003</a>].</p><ul><li class="half_rhythm"><div>Although complete clinical remission (for &#x0003e;5 years) can be successfully achieved, in a proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals outcome is complicated by relapse or the development of a second malignancy [<a class="bk_pop" href="#nijmegen.REF.dembowskabaginska.2009.186">Dembowska-Baginska et al 2009</a>, <a class="bk_pop" href="#nijmegen.REF.bienemann.2011.468">Bienemann et al 2011</a>].</div></li><li class="half_rhythm"><div>For individuals who achieve first remission, hematopoietic stem cell transplantation (HSCT) may be considered:</div><ul><li class="half_rhythm"><div>The first successful bone marrow transplantation was performed in an individual with NBS who was initially misdiagnosed with Fanconi anemia (FA) [<a class="bk_pop" href="#nijmegen.REF.gennery.2004.214">Gennery et al 2004</a>, <a class="bk_pop" href="#nijmegen.REF.gennery.2005.239">Gennery et al 2005</a>].</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#nijmegen.REF.wolskaku_nierz.2015.538">Wolska-Ku&#x0015b;nierz et al [2015]</a> summarized the results of HSCT in 14 individuals with NBS, nine of whom were alive [<a class="bk_pop" href="#nijmegen.REF.gennery.2005.239">Gennery et al 2005</a>, <a class="bk_pop" href="#nijmegen.REF.new.2005.494">New et al 2005</a>, <a class="bk_pop" href="#nijmegen.REF.albert.2010.622">Albert et al 2010</a>].</div></li><li class="half_rhythm"><div><a class="bk_pop" href="#nijmegen.REF.wo_niak.2015.e51">Wo&#x0017a;niak et al [2015]</a> reported the successful use of non-myeloablative umbilical cord transplantation in a child age 19 months with NBS and severe combined immune deficiency.</div></li><li class="half_rhythm"><div>Further long-term follow up is needed to determine the outcome of HSCT in individuals with NBS.</div></li></ul></li></ul><p><b>Puberty and fertility.</b> Females with NBS who are of pubertal age should be referred for evaluation by a gynecologist and/or endocrinologist to evaluate for hypergonadotropic hypogonadism.</p><ul><li class="half_rhythm"><div>Hormonal replacement therapy should be considered with careful monitoring of secondary sexual characteristics and uterus development.</div></li><li class="half_rhythm"><div>Females are infertile; similarly, no male paternity has been reported.</div></li></ul></div><div id="nijmegen.Surveillance"><h3>Surveillance</h3><p><b>Affected individuals</b></p><ul><li class="half_rhythm"><div>Periodic follow-up to monitor developmental progress, physical growth (including weight, length/height, and head circumference) and frequency of infections; monitoring for weight loss, which may signal the presence of a malignancy</div></li><li class="half_rhythm"><div>Lifelong monitoring of immune biomarkers to include the parameters listed in <a href="#nijmegen.Evaluations_Following_Initial_D">Evaluations Following Initial Diagnosis</a></div></li><li class="half_rhythm"><div>Careful follow up by oncologist: in individuals with NBS who are immunodeficient symptoms of lymphoid malignancies can be misleading.</div></li><li class="half_rhythm"><div>Monitoring for pubertal progression in both females and males and for premature ovarian insufficiency in females [<a class="bk_pop" href="#nijmegen.REF.chrzanowska.2010b.88">Chrzanowska et al 2010b</a>]</div></li><li class="half_rhythm"><div>Breast self-examination and ultrasonographic evaluation recommended in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> females</div></li></ul><p><b>Carriers (heterozygotes)</b></p><ul><li class="half_rhythm"><div><b>Parents.</b> As obligate carriers, parents should be monitored for malignancy, in particular breast cancer in women and prostate cancer in men. No consensus tumor screening protocols for carriers have been published.</div></li><li class="half_rhythm"><div><b>At-risk sibs.</b> Evidence of cancer risk in young carriers is insufficient to warrant screening in childhood.</div></li></ul></div><div id="nijmegen.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Because the cells from individuals with NBS are as radiosensitive in vitro as those from individuals with <a href="/books/n/gene/ataxia-telangiectas/">ataxia-telangiectasia</a> (another <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> instability syndrome), conventional doses of radiation used in radiotherapy could be lethal in individuals with NBS. Family members should be made aware of this risk so that they can discuss appropriate treatment options if a malignancy is diagnosed.</p><p>Similarly, unnecessary exposure to ionizing radiation should be avoided; instead of radiograph or CT scan, MR imaging and ultrasound examination are strongly recommended.</p></div><div id="nijmegen.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>NBN</i> pathogenic variants identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> to apparently asymptomatic sibs of a proband and young adult relatives at risk of being carriers (heterozygotes) in order to identify as early as possible those who would benefit from monitoring for malignancy (see <a href="#nijmegen.Surveillance">Surveillance</a>) and to inform treatment options if a malignancy is diagnosed (see <a href="#nijmegen.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</p><p>See <a href="#nijmegen.Related_Genetic_Counseling_Issu">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="nijmegen.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="nijmegen.Genetic_Counseling"><h2 id="_nijmegen_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="nijmegen.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>NBS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="nijmegen.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>NBN</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes are asymptomatic; however, in some populations, there is evidence of increased cancer risk for heterozygotes [<a class="bk_pop" href="#nijmegen.REF.seemanov_.2007.1875">Seemanov&#x000e1; et al 2007</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic; however, in some populations, there is evidence of an increased cancer risk for heterozygotes [<a class="bk_pop" href="#nijmegen.REF.seemanov_.2007.1875">Seemanov&#x000e1; et al 2007</a>].</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> No <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been reported to reproduce.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>NBN</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="nijmegen.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>NBN</i> pathogenic variants in the family.</p></div><div id="nijmegen.Related_Genetic_Counseling_Issu"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#nijmegen.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are carriers or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="nijmegen.Prenatal_Testing_and_Preimplant"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>NBN</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for NBS are possible.</p></div></div><div id="nijmegen.Resources"><h2 id="_nijmegen_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li></ul></div><div id="nijmegen.Molecular_Genetics"><h2 id="_nijmegen_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="nijmegen.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Nijmegen Breakage Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1176/table/nijmegen.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nijmegen.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_nijmegen.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_nijmegen.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_nijmegen.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_nijmegen.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_nijmegen.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_nijmegen.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_nijmegen.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4683" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>NBN</i></a></td><td headers="hd_b_nijmegen.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4683" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">8q21<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_nijmegen.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O60934" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Nibrin</a></td><td headers="hd_b_nijmegen.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/NBN" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NBN @ LOVD</a></td><td headers="hd_b_nijmegen.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=NBN" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NBN</a></td><td headers="hd_b_nijmegen.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBN[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NBN</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="nijmegen.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="nijmegen.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Nijmegen Breakage Syndrome (<a href="/omim/251260,602667" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1176/table/nijmegen.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nijmegen.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/251260" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">251260</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NIJMEGEN BREAKAGE SYNDROME; NBS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/602667" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">602667</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NIBRIN; NBN</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>NBN</i> is encoded in 16 exons and spans approximately 51 kb of DNA. The entire <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> has been sequenced. The gene encodes two transcripts of 4.6 kb (<a href="/nuccore/NM_002485.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002485.4</a>) and 2.4 kb [<a class="bk_pop" href="#nijmegen.REF.carney.1998.477">Carney et al 1998</a>] that are expressed in all tissues examined and differ only in their site of polyadenylation. Transcript <a href="/nuccore/NM_002485.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002485.4</a> has 16 exons and encodes a protein of 754 amino acids. For a detailed summary of gene and protein information, see <a href="/books/NBK1176/#nijmegen.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Most disease-causing <i>NBN</i> alleles identified to date are predicted to result in truncation of the nibrin protein (see <a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">Table 3</a>). The c.657_661del5 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is most common, accounting for the majority of all disease alleles in <i>NBN</i>. Other pathogenic variants (<a class="figpopup" href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object" rid-figpopup="fignijmegenTselectednbnpathogenicvaria" rid-ob="figobnijmegenTselectednbnpathogenicvaria">Table 3</a>) occur in one or a small number of families. <i>NBN</i> <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> is always detectable in cell lines from individuals with NBS, but full-length nibrin protein is not detectable by western blotting.</p><p>One <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, p.Tyr363Ter, was detected <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> in an individual diagnosed with atypical <a href="/books/n/gene/fa/">Fanconi anemia</a>, as well as several <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members with similar clinical features [<a class="bk_pop" href="#nijmegen.REF.gennery.2004.214">Gennery et al 2004</a>, <a class="bk_pop" href="#nijmegen.REF.new.2005.494">New et al 2005</a>]. These findings highlight the lack of disease specificity in assays that test for <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> to DNA crosslinking agents.</p><p>While the overwhelming majority of persons with NBS have <i>NBN</i> <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> truncating alleles, <a class="bk_pop" href="#nijmegen.REF.seemanov_.2006.218">Seemanov&#x000e1; et al [2006]</a> have described a unique set of monozygotic twins who are <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for the common c.657_661del5 <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant, c.643C&#x0003e;T resulting in p.Arg215Trp. These twins had a more severe clinical course than typical for NBS (particularly with respect to neurologic features) but lacked the cellular <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> instability and radiation sensitivity characteristic of the disorder.</p><div id="nijmegen.T.selected_nbn_pathogenic_varia" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Selected <i>NBN</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1176/table/nijmegen.T.selected_nbn_pathogenic_varia/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nijmegen.T.selected_nbn_pathogenic_varia_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequence</th><th id="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Origin</th><th id="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"># of Families in Whom Pathogenic Variant is Seen</th></tr></thead><tbody><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.330T&#x0003e;G</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr110Ter</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_3" rowspan="13" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_002485.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_002485<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="/protein/NP_002476.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_002476<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.643C&#x0003e;T</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg215Trp</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Slavic</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.657_661del5<br />(657del5)</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys219AsnfsTer15</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Slavic</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.681delT</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe227LeufsTer4</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Russian</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.698_701del4</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys233SerfsTer4</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">English</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.741_742dup<br />(742insGG)</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu248GlyfsTer5</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Italian</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.835_838del4</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln279ProfsTer1</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Italian</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.842insT</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu281PhefsTer3</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Mexican</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.900del25</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly301LysfsTer5</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Moroccan</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.976C&#x0003e;T</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln326Ter</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Dutch</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1089C&#x0003e;A</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr363Ter</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Pakistani&#x000a0;<sup>2</sup></td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1125G&#x0003e;A</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp375Ter</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1</td></tr><tr><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1142delC</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Pro381GlnfsTer22</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_4" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">Canadian</td><td headers="hd_h_nijmegen.T.selected_nbn_pathogenic_varia_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="nijmegen.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="nijmegen.TF.3.2"><p class="no_margin">Individual originally diagnosed as having <a href="/books/n/gene/fa/">Fanconi anemia</a> with atypical clinical features. See <a href="#nijmegen.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The <i>NBN</i> protein product is nibrin, also known as p95. Nibrin is a protein of 85 kd in mass that is ubiquitously expressed. There is no sequence homology between nibrin and other known proteins. However, nibrin contains a forkhead-associated <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> and two breast cancer carboxy-terminal domains, which are involved in cellular responses to DNA damage. In normal fibroblasts, nibrin is associated with two other proteins involved in DNA repair, hMre11 and hRad50. On exposure to ionizing radiation, this complex of proteins, including nibrin, forms nuclear foci at sites where DNA repair has taken place. Nibrin targets the <i>NBN</i>/Mre11/Rad50 complex to sites of double-strand breaks and interacts with ATM kinase to coordinate cell cycle arrest with DNA repair [<a class="bk_pop" href="#nijmegen.REF.carney.1998.477">Carney et al 1998</a>, <a class="bk_pop" href="#nijmegen.REF.matsuura.2004.65">Matsuura et al 2004</a>, <a class="bk_pop" href="#nijmegen.REF.falck.2005.605">Falck et al 2005</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Most known <i>NBN</i> pathogenic variants are predicted to result in truncation of the nibrin protein (often termed p70). All known NBS pathogenic variants occur in exons 6-10; presumably reflecting a requirement for production of a C-terminal protein fragment of nibrin that occurs by translational re-initiation mechanism [<a class="bk_pop" href="#nijmegen.REF.maser.2001.417">Maser et al 2001</a>]. The requirement that protein termination and re-initiation occur in the same reading frame potentially limits the pathogenic variants that can give rise to NBS. Knockout mice <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles of <i>NBN</i> are embryonic lethal, suggesting that the partial protein produced from <i>NBN</i> alleles in humans is necessary for survival.</p></div><div id="nijmegen.References"><h2 id="_nijmegen_References_">References</h2><div id="nijmegen.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.albert.2010.622">Albert MH, Gennery AR, Greil J, Cale CM, Kalwak K, Kondratenko I, Mlynarski W, Notheis G, F&#x000fc;hrer M, Schmid I, Belohradsky BH. Successful SCT for Nijjmegen breakage syndrome. <span><span class="ref-journal">Bone Marrow Transplant. </span>2010;<span class="ref-vol">45</span>:622–6.</span> [<a href="/pubmed/19684627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19684627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.altmann.2016.137">Altmann T, Gennery AR. DNA ligase IV syndrome; a review. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2016;<span class="ref-vol">11</span>:137.</span> [<a href="/pmc/articles/PMC5055698/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5055698</span></a>] [<a href="/pubmed/27717373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27717373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.bakhshi.2003.248">Bakhshi S, Cerosaletti KM, Concannon P, Bawle EV, Fontanesi J, Gatti RA, Bhambhani K. Medulloblastoma with adverse reaction to radiation therapy in nijmegen breakage syndrome. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2003;<span class="ref-vol">25</span>:248–51.</span> [<a href="/pubmed/12621246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12621246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.barbi.1991.44">Barbi G, Scheres JM, Schindler D, Taalman RD, Rodens K, Mehnert K, M&#x000fc;ller M, Seyschab H. Chromosome instability and X-ray hypersensitivity in a microcephalic and growth-retarded child. <span><span class="ref-journal">Am J Med Genet. </span>1991;<span class="ref-vol">40</span>:44–50.</span> [<a href="/pubmed/1887849" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1887849</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.benomran.2005.283">Ben-Omran TI, Cerosaletti K, Concannon P, Weitzman S, Nezarati MM. A patient with mutations in NDA ligase IV: clinical features and overlap with Nijmegen breakage syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2005;<span class="ref-vol">137A</span>:283–7.</span> [<a href="/pubmed/16088910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16088910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.bienemann.2011.468">Bienemann K, Burkhardt B, Modlich S, Meyer U, M&#x000f6;ricke A, Bienemann K, Mauz-K&#x000f6;rholz C, Escherich G, Zimmermann M, K&#x000f6;rholz D, Janka-Schaub G, Schrappe M, Reiter A, Borkhardt A. Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey. <span><span class="ref-journal">Br J Haematol. </span>2011;<span class="ref-vol">155</span>:468–76.</span> [<a href="/pubmed/21923652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21923652</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.carney.1998.477">Carney JP, Maser RS, Olivares H, Davis EM, Le Beau M, Yates JR 3rd, Hays L, Morgan WF, Petrini JH. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. <span><span class="ref-journal">Cell. </span>1998;<span class="ref-vol">93</span>:477–86.</span> [<a href="/pubmed/9590181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9590181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.chrzanowska.1997.309">Chrzanowska K, Stumm M, Bialecka M, Saar K, Bernatowska-Matuszkiewicz E, Michalkiewicz J, Barszcz S, Reis A, Wegner RD. Linkage studies exclude the AT-V gene(s) from the translocation breakpoints in an AT-V patient. <span><span class="ref-journal">Clin Genet. </span>1997;<span class="ref-vol">51</span>:309–13.</span> [<a href="/pubmed/9212178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9212178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.chrzanowska.2012.13">Chrzanowska KH, Gregorek H, Dembowska-Bagi&#x00144;ska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). <span><span class="ref-journal">Orphanet J Rare Dis. </span>2012;<span class="ref-vol">7</span>:13.</span> [<a href="/pmc/articles/PMC3314554/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3314554</span></a>] [<a href="/pubmed/22373003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22373003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.chrzanowska.2000.s73">Chrzanowska KH, Romer T, Krajewska-Walasek M, Gajtko-Metera M, Szarras-Czapnik M, Abramezuk D, Varon R, Rysiewski H, Janas R, Syczewska M. Evidence for a high rate of gonadal failure in female patients with Nijmegen breakage syndrome. <span><span class="ref-journal">Eur J Hum Genet. </span>2000;<span class="ref-vol">8</span>:S73.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.chrzanowska.2010a.3133">Chrzanowska KH, Szarras-Czapnik M, Gajdulewicz M, Kalina MA, Gajtko-Metera M, Walewska-Wolf M, Szufladowicz-Wozniak J, Rysiewski H, Gregorek H, Cukrowska B, Syczewska M, Piekutowska-Abramczuk D, Janas R, Krajewska-Walasek M. High prevalence of primary ovarian insufficiency in girls and young women with Nijmegen breakage syndrome: evidence from a longitudinal study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2010a;<span class="ref-vol">95</span>:3133–40.</span> [<a href="/pubmed/20444919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20444919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.chrzanowska.2010b.88">Chrzanowska KH, Szarras-Czapnik M, Kalina M, Gajdulewicz M, Gajtko-Metera M, Rysiewski H, Dembowska-Bagi&#x00144;ska B, Gregorek H, Piekutowska-Abramczuk D, Ciara E, Syczewska M, Janas R, Krajewska-Walasek M. Gonadal function in male patients with Nijmegen breakage syndrome, a cancer-prone disease with the DNA repair defect. <span><span class="ref-journal">Eur J Hum Genet. </span>2010b;<span class="ref-vol">18</span>:88–9.</span> Abstract.</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.ciara.2010.325">Ciara E, Piekutowska-Abramczuk D, Popowska E, Grajkowska W, Barszcz S, Perek D, Dembowska-Bagi&#x00144;ska B, Perek-Polnik M, Kowalewska E, Czaj&#x00144;ska A, Syczewska M, Czornak K, Krajewska-Walasek M, Roszkowski M, Chrzanowska KH. Heterozygous germ-line mutations in the NBN gene predispose to medulloblastoma in pediatric patients. <span><span class="ref-journal">Acta Neuropathol. </span>2010;<span class="ref-vol">119</span>:325–34.</span> [<a href="/pubmed/19908051" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19908051</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.curry.1989.270">Curry CJ, O'Lague P, Tsai J, Hutchison HT, Jaspers NG, Wara D, Gatti RA. ATFresno: a phenotype linking ataxia-telangiectasia with the Nijmegen breakage syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>1989;<span class="ref-vol">45</span>:270–5.</span> [<a href="/pmc/articles/PMC1683342/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1683342</span></a>] [<a href="/pubmed/2491181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2491181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.cybulski.2004.1215">Cybulski C, Gorski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojc B, Jakubowska A, Matyjasik J, Zlowocka E, Sikorski A, Narod SA, Lubinski J. NBS1 is a prostate cancer susceptibility gene. <span><span class="ref-journal">Cancer Res. </span>2004;<span class="ref-vol">64</span>:1215–9.</span> [<a href="/pubmed/14973119" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14973119</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.dembowskabaginska.2009.186">Dembowska-Baginska B, Perek D, Brozyna A, Wakulinska A, Olczak-Kowalczyk D, Gladkowska-Dura M, Grajkowska W, Chrzanowska KH. Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage syndrome (NBS). <span><span class="ref-journal">Pediatr Blood Cancer. </span>2009;<span class="ref-vol">52</span>:186–90.</span> [<a href="/pubmed/18937313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18937313</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.distel.2003.44">Distel L, Neubauer S, Varon R, Holter W, Grabenbauer G. Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. <span><span class="ref-journal">Med Pediatr Oncol. </span>2003;<span class="ref-vol">41</span>:44–8.</span> [<a href="/pubmed/12764742" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12764742</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.dutrannoy.2010.1059">Dutrannoy V, Demuth I, Baumann U, Schindler D, Konrat K, Neitzel H, Gillessen-Kaesbach G, Radszewski J, Rothe S, Schellenberger MT, N&#x000fc;rnberg G, N&#x000fc;rnberg P, Teik KW, Nallusamy R, Reis A, Sperling K, Digweed M, Varon R. Clinical variability and novel mutations in the NHEJ1 gene in patients with a Nijmegen breakage syndrome-like phenotype. <span><span class="ref-journal">Hum Mutat. </span>2010;<span class="ref-vol">31</span>:1059–68.</span> [<a href="/pubmed/20597108" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20597108</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.falck.2005.605">Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. <span><span class="ref-journal">Nature. </span>2005;<span class="ref-vol">434</span>:605–11.</span> [<a href="/pubmed/15758953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15758953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.gennery.2004.214">Gennery AR, Slatter MA, Bhattacharya A, Barge D, Haigh S, O'Driscoll M, Coleman R, Abinun M, Flood TJ, Cant AJ, Jeggo PA. The clinical and biological overlap between Nijmegen Breakage Syndrome and Fanconi anemia. <span><span class="ref-journal">Clin Immunol. </span>2004;<span class="ref-vol">113</span>:214–9.</span> [<a href="/pubmed/15451479" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15451479</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.gennery.2005.239">Gennery AR, Slatter MA, Bhattacharya A, Jeggo PA, Abinun M, Flood TJ, Cant AJ. Bone marrow transplantation for Nijmegen breakage syndrome. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2005;<span class="ref-vol">27</span>:239.</span> [<a href="/pubmed/15838402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15838402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.gilad.1998.551">Gilad S, Chessa L, Khosravi R, Russell P, Galanty Y, Piane M, Gatti RA, Jorgensen TJ, Shiloh Y, Bar-Shira A. Genotype-phenotype relationships in ataxia-telangiectasia and variants. <span><span class="ref-journal">Am J Hum Genet. </span>1998;<span class="ref-vol">62</span>:551–61.</span> [<a href="/pmc/articles/PMC1376949/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1376949</span></a>] [<a href="/pubmed/9497252" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9497252</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.g_adkowskadura.2008.337">G&#x00142;adkowska-Dura M, Dzierzanowska-Fangrat K, Dura WT, van Krieken JH, Chrzanowska KH, van Dongen JJ, Langerak AW. Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation. <span><span class="ref-journal">J Pathol. </span>2008;<span class="ref-vol">216</span>:337–44.</span> [<a href="/pubmed/18788073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18788073</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.gregorek.2002.319">Gregorek H, Chrzanowska KH, Michalkiewicz J, Syczewska M, Madalinski K. Heterogeneity of humoral immune abnormalities in children with Nijmegen breakage syndrome: an 8-year follow-up study in a single centre. <span><span class="ref-journal">Clin Exp Immunol. </span>2002;<span class="ref-vol">130</span>:319–24.</span> [<a href="/pmc/articles/PMC1906518/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1906518</span></a>] [<a href="/pubmed/12390322" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12390322</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.hiel.2001.e19">Hiel JA, Weemaes CM, van Engelen BG, Smeets D, Ligtenberg M, van Der Burgt I, van Den Heuvel LP, Cerosaletti KM, Gabre&#x000eb;ls FJ, Concannon P. Nijmegen breakage syndrome in a Dutch patient not resulting from a defect in NBS1. <span><span class="ref-journal">J Med Genet. </span>2001;<span class="ref-vol">38</span>:E19.</span> [<a href="/pmc/articles/PMC1734895/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734895</span></a>] [<a href="/pubmed/11389166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11389166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.jaspers.1988.259">Jaspers NG, Gatti RA, Baan C, Linssen PC, Bootsma D. Genetic complementation analysis of ataxia telangiectasia and Nijmegen breakage syndrome: a survey of 50 patients. <span><span class="ref-journal">Cytogenet Cell Genet. </span>1988;<span class="ref-vol">49</span>:259–63.</span> [<a href="/pubmed/3248383" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3248383</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.maraschio.1986.353">Maraschio P, Peretti D, Lambiase S, Lo Curto F, Caufin D, Gargantini L, Minoli L, Zuffardi O. New chromosome instability disorder. <span><span class="ref-journal">Clin Genet. </span>1986;<span class="ref-vol">30</span>:353–65.</span> [<a href="/pubmed/3802554" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3802554</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.maser.2001.417">Maser RS, Zinkel R, Petrini JH. An alternative mode of translation permits production of a variant NBS1 protein from the common Nijmegen breakage syndrome allele. <span><span class="ref-journal">Nat Genet. </span>2001;<span class="ref-vol">27</span>:417–21.</span> [<a href="/pubmed/11279524" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11279524</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.matsuura.2004.65">Matsuura S, Kobayashi J, Tauchi H, Komatsu K. Nijmegen breakage syndrome and DNA double strand break repair by NBS1 complex. <span><span class="ref-journal">Adv Biophys. </span>2004;<span class="ref-vol">38</span>:65–80.</span> [<a href="/pubmed/15476893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15476893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.maurer.2010.211">Maurer MH, Hoffmann K, Sperling K, Varon R. High prevalence of the NBN gene mutation c.657-661del5 in Southeast Germany. <span><span class="ref-journal">J Appl Genet. </span>2010;<span class="ref-vol">51</span>:211–4.</span> [<a href="/pubmed/20453309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20453309</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.meyer.2004.169">Meyer S, Kingston H, Taylor AM, Byrd PJ, Last JI, Brennan BM, Trueman S, Kelsey A, Taylor GM, Eden OB. Rhabdomyosarcoma in Nijmegen breakage syndrome: strong association with perianal primary site. <span><span class="ref-journal">Cancer Genet Cytogenet. </span>2004;<span class="ref-vol">154</span>:169–74.</span> [<a href="/pubmed/15474156" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15474156</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.micha_kiewicz.2003.482">Micha&#x00142;kiewicz J, Barth C, Chrzanowska K, Gregorek H, Syczewska M, Weemaes CM, Madali&#x00144;ski K, Stachowski J. Abnormalities in the T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome. <span><span class="ref-journal">Clin Exp Immunol. </span>2003;<span class="ref-vol">134</span>:482–90.</span> [<a href="/pmc/articles/PMC1808880/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1808880</span></a>] [<a href="/pubmed/14632755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14632755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.murray.2015.412">Murray JE, van der Burg M, IJspeert H, Carroll P, Wu Q, Ochi T, Leitch A, Miller ES, Kysela B, Jawad A, Bottani A, Brancati F, Cappa M, Cormier-Daire V, Deshpande C, Faqeih EA, Graham GE, Ranza E, Blundell TL, Jackson AP, Stewart GS, Bicknell LS. Mutations in the NHEJ component XRCC4 cause primordial dwarfism. <span><span class="ref-journal">Am J Hum Genet. </span>2015;<span class="ref-vol">96</span>:412–24.</span> [<a href="/pmc/articles/PMC4375537/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4375537</span></a>] [<a href="/pubmed/25728776" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25728776</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.new.2005.494">New HV, Cale CM, Tischkowitz M, Jones A, Telfer P, Veys P, D'Andrea A, Mathew CG, Hann I. Nijmegen breakage syndrome diagnosed as Fanconi anaemia. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2005;<span class="ref-vol">44</span>:494–9.</span> [<a href="/pubmed/15593232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15593232</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.odriscoll.2001.1175">O'Driscoll M, Cerosaletti KM, Girard PM, Dai Y, Stumm M, Kysela B, Hirsch B, Gennery A, Palmer SE, Seidel J, Gatti RA, Varon R, Oettinger MA, Neitzel H, Jeggo PA, Concannon P. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. <span><span class="ref-journal">Mol Cell. </span>2001;<span class="ref-vol">8</span>:1175–85.</span> [<a href="/pubmed/11779494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11779494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.odriscoll.2003.497">O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">33</span>:497–501.</span> [<a href="/pubmed/12640452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12640452</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.pasic.2012.138">Pasic S, Kandolf-Sekulovic L, Djuricic S, Zolotarevski L, Simic R, Abinun M. Necrobiotic cutaneous granulomas in Nijmegen breakage syndrome. <span><span class="ref-journal">J Investig Allergol Clin Immunol. </span>2012;<span class="ref-vol">22</span>:138–40.</span> [<a href="/pubmed/22533239" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22533239</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.pastorczak.2016.126">Pastorczak A, Szczepanski T, Mlynarski W. Clinical course and therapeutic implications for lymphoid malignancies in Nijmegen breakage syndrome. <span><span class="ref-journal">Eur J Med Genet. </span>2016;<span class="ref-vol">59</span>:126–32.</span> [<a href="/pubmed/26826318" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26826318</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.resnick.2002.355">Resnick IB, Kondratenko I, Togoev O, Vasserman N, Shagina I, Evgrafov O, Tverskaya S, Cerosaletti KM, Gatti RA, Concannon P. Nijmegen breakage syndrome: clinical characteristics and mutation analysis in eight unrelated Russian families. <span><span class="ref-journal">J Pediatr. </span>2002;<span class="ref-vol">140</span>:355–61.</span> [<a href="/pubmed/11953735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11953735</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.rosin.2015.3708">Rosin N, Elcioglu NH, Beleggia F, Isg&#x000fc;ven P, Altm&#x000fc;ller J, Thiele H, Steindl K, Joset P, Rauch A, N&#x000fc;rnberg P. Wollnik B8, Yigit G1. Mutations in XRCC4 cause primary microcephaly, short stature and increased genomic instability. <span><span class="ref-journal">Hum Mol Genet. </span>2015;<span class="ref-vol">24</span>:3708–17.</span> [<a href="/pubmed/25839420" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25839420</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.seeman.2004.195">Seeman P, Gebertova K, Paderova K, Sperling K, Seemanova E. Nijmegen breakage syndrome in 13% of age-matched Czech children with primary microcephaly. <span><span class="ref-journal">Pediatr Neurol. </span>2004;<span class="ref-vol">30</span>:195–200.</span> [<a href="/pubmed/15033202" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15033202</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.seemanov_.2007.1875">Seemanov&#x000e1; E, Jarolim P, Seeman P, Varon R, Digweed M, Swift M, Sperling K. Cancer risk of heterozygotes with the NBN founder mutation. <span><span class="ref-journal">J Natl Cancer Inst. </span>2007;<span class="ref-vol">99</span>:1875–80.</span> [<a href="/pubmed/18073374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18073374</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.seemanov_.1985.639">Seemanov&#x000e1; E, Passarge E, Beneskova D, Houstek J, Kasal P, Sevcikova M. Familial microcephaly with normal intelligence, immunodeficiency, and risk for lymphoreticular malignancies: a new autosomal recessive disorder. <span><span class="ref-journal">Am J Med Genet. </span>1985;<span class="ref-vol">20</span>:639–48.</span> [<a href="/pubmed/3857858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3857858</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.seemanov_.2006.218">Seemanov&#x000e1; E, Sperling K, Neitzel H, Varon R, Hadac J, Butova O, Schr&#x000f6;ck E, Seeman P, Digweed M. Nijmegen breakage syndrome (NBS) with neurological abnormalities and without chromosomal instability. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:218–24.</span> [<a href="/pmc/articles/PMC2563240/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563240</span></a>] [<a href="/pubmed/16033915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16033915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.steffen.2004.67">Steffen J, Varon R, Mosor M, Maneva G, Maurer M, Stumm M, Nowakowska D, Rubach M, Kosakowska E, Ruka W, Nowecki Z, Rutkowski P, Demkow T, Sadowska M, Bidzinski M, Gawrychowski K, Sperling K. Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. <span><span class="ref-journal">Int J Cancer. </span>2004;<span class="ref-vol">111</span>:67–71.</span> [<a href="/pubmed/15185344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15185344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.varon.2006.679">Varon R, Dutrannoy V, Weikert G, Tanzarella C, Antoccia A, St&#x000f6;ckl L, Spadoni E, Kr&#x000fc;ger LA, di Masi A, Sperling K, Digweed M, Maraschio P. Mild Nijmegen breakage syndrome phenotype due to alternative splicing. <span><span class="ref-journal">Hum Mol Genet. </span>2006;<span class="ref-vol">15</span>:679–89.</span> [<a href="/pubmed/16415040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16415040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.waltes.2009.605">Waltes R, Kalb R, Gatei M, Kijas AW, Stumm M, Sobeck A, Wieland B, Varon R, Lerenthal Y, Lavin MF, Schindler D, Dork T. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. <span><span class="ref-journal">Am J Hum Genet. </span>2009;<span class="ref-vol">84</span>:605–16.</span> [<a href="/pmc/articles/PMC2681000/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2681000</span></a>] [<a href="/pubmed/19409520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19409520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.warcoin.2009.424">Warcoin M, Lespinasse J, Despouy G, Dubois d'Enghien C, Laug&#x000e9; A, Portno&#x000ef; MF, Christin-Maitre S, Stoppa-Lyonnet D, Stern MH. Fertility defects revealing germline biallelic nonsense NBN mutations. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:424–30.</span> [<a href="/pubmed/19105185" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19105185</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.weemaes.1981.557">Weemaes CM, Hustinx TW, Scheres JM, van Munster PJ, Bakkeren JA, Taalman RD. A new chromosomal instability disorder: the Nijmegen breakage syndrome. <span><span class="ref-journal">Acta Paediatr Scand. </span>1981;<span class="ref-vol">70</span>:557–64.</span> [<a href="/pubmed/7315300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7315300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.wegner.1999">Wegner RD, Chrzanowska KH, Sperling K, Stumm M. Ataxia-telangiectasia variants (Nijmegen breakage syndrome). In: Ochs HD, Smith CIE, Puck JM, eds. <em>Primary Immunodeficiency Diseases, a Molecular and Genetic Approach.</em> Oxford, UK: Oxford University Press; 1999:324-34.</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.wolskaku_nierz.2015.538">Wolska-Ku&#x0015b;nierz B, Gregorek H, Chrzanowska K, Pi&#x00105;tosa B, Pietrucha B, Heropolita&#x00144;ska-Pliszka E, Pac M, Klaudel-Dreszler M, Kostyuchenko L, Pasic S, Marodi L, Belohradsky BH, &#x0010c;i&#x0017e;n&#x000e1;r P, Shcherbina A, Kilic SS, Baumann U, Seidel MG, Gennery AR, Syczewska M, Miko&#x00142;u&#x00107; B, Ka&#x00142;wak K, Styczy&#x00144;ski J, Pieczonka A, Drabko K, Wakuli&#x00144;ska A, Gathmann B, Albert MH, Skar&#x0017c;y&#x00144;ska U, Bernatowska E. Nijmegen breakage syndrome: clinical and immunological features, long-term outcome and treatment options - a retrospective analysis. <span><span class="ref-journal">J Clin Immunol. </span>2015;<span class="ref-vol">35</span>:538–49.</span> [<a href="/pubmed/26271390" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26271390</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.wo_niak.2015.e51">Wo&#x0017a;niak M, Krzywo&#x00144; M, Ho&#x00142;da MK, Go&#x0017a;dzik J. Reduced-intensity conditioning umbilical cord blood transplantation in Nijmegen breakage syndrome. <span><span class="ref-journal">Pediatr Transplant. </span>2015;<span class="ref-vol">19</span>:E51–5.</span> [<a href="/pubmed/25523867" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25523867</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nijmegen.REF.yoo.2008.418">Yoo J, Wolgamot G, Torgerson TR, Sidbury R. Cutaneous noncaseating granulomas associated with Nijmegen breakage syndrome. <span><span class="ref-journal">Arch Dermatol. </span>2008;<span class="ref-vol">144</span>:418–9.</span> [<a href="/pubmed/18347309" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18347309</span></a>]</div></li></ul></div></div><div id="nijmegen.Chapter_Notes"><h2 id="_nijmegen_Chapter_Notes_">Chapter Notes</h2><div id="nijmegen.Author_History"><h3>Author History</h3><p>Krystyna H Chrzanowska, MD, PhD (2017-present) <br />Patrick Concannon, PhD; University of Florida Genetics Institute (1999-2014)<br />Ilja Demuth, PhD (2014-present)<br />Martin Digweed, PhD; Universit&#x000e4;tsmedizin Berlin (2014-2017)<br />Richard Gatti, MD; University of California Los Angeles (1999-2014)<br />Raymonda Varon, PhD (2014-present)</p></div><div id="nijmegen.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>2 February 2017 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>8 May 2014 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 March 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 June 2005 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 March 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>17 May 1999 (me) Review posted live</div></li><li class="half_rhythm"><div>5 January 1999 (pc) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1176</span><span class="label">PMID: <a href="/pubmed/20301355" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301355</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/npc/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/nkh/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1176&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1176/?report=reader">PubReader</a></li><li><a href="/books/NBK1176/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1176" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1176" style="display:none" title="Cite this Page"><div class="bk_tt">Varon R, Demuth I, Chrzanowska KH. Nijmegen Breakage Syndrome. 1999 May 17 [Updated 2017 Feb 2]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1176/pdf/Bookshelf_NBK1176.pdf">PDF version of this page</a> (470K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#nijmegen.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#nijmegen.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#nijmegen.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#nijmegen.Genetically_Related_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related Disorders</a></li><li><a href="#nijmegen.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#nijmegen.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#nijmegen.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#nijmegen.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#nijmegen.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#nijmegen.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#nijmegen.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4683[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NBN</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1496464" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1496464" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1496464" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1496464" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22373003" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nijmegen breakage syndrome (NBS).</a><span class="source">[Orphanet J Rare Dis. 2012]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Nijmegen breakage syndrome (NBS).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chrzanowska KH, Gregorek H, Dembowska-Bagińska B, Kalina MA, Digweed M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2012 Feb 28; 7:13. Epub 2012 Feb 28.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301584" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Severe Combined Immunodeficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Allenspach E, Rawlings DJ, Scharenberg AM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301501" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Recessive</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Polycystic Kidney Disease, Autosomal Recessive<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sweeney WE, Avner ED. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301656" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adenosine Deaminase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adenosine Deaminase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hershfield M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301355" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301355" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040d7fdde0891169539156">Nijmegen Breakage Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Nijmegen Breakage Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:31:43-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88EFBEE040D1D10000000000260011&amp;ncbi_session=CE88EFBEE040D7F1_0038SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1176%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1176&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1176/&amp;ncbi_pagename=Nijmegen Breakage Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88EFBEE040D7F1_0038SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>